15-White Dots APP-Coo-Test: a reliable touch-screen application for assessing upper limb movement impairment in patients with cerebellar ataxias.
Cerebellar ataxia
Neurodegenerative diseases
Quantitative assessment
SARA
Touch-screen application
Upper limb movement impairment
Journal
Journal of neurology
ISSN: 1432-1459
Titre abrégé: J Neurol
Pays: Germany
ID NLM: 0423161
Informations de publication
Date de publication:
Jul 2019
Jul 2019
Historique:
received:
26
01
2019
accepted:
27
03
2019
revised:
23
03
2019
pubmed:
8
4
2019
medline:
31
12
2019
entrez:
8
4
2019
Statut:
ppublish
Résumé
The use of objective measurements is essential to assess disease progression and to evaluate the effectiveness of rehabilitation protocols and clinical treatments. The purpose of this study was to develop a touch-screen application, that we named 15-White Dots APP-Coo-Test (15-WDACT), able to carry out quantitative and objective measurements of the rapid and coordinated upper limb movements, typically impaired in patients with cerebellar ataxias (CA). A total of 87 CA patients and 170 healthy subjects participated in this study. The subject was asked to touch with their index finger a white dot, appearing consecutively and randomly on the screen at different positions, for a total of 15 dots per session. The score is the execution time of a single session. 15-WDACT measurements have highly correlated with the scores obtained with the Scale for the Assessment and Rating of Ataxia (SARA), with the Composite Cerebellar Functional Severity (CCFS) and with the measurements obtained using two validated evaluating systems, i.e., the Nine Hole Pegboard test (9HPT) and the Click Test. We also observed high internal consistency and an excellent intra-rater and test-retest reliability. We found a small Standard Error of Measurement (SEM) and an excellent Minimal Detectable Change (MDC), indicating that even small variations in the 15-WDACT measurements are to be associated with real changes in performance. We have concluded that 15-WDACT is an easy, fast and reliable tool to assess the severity of the upper limb ataxia in patients with CA.
Sections du résumé
BACKGROUND
BACKGROUND
The use of objective measurements is essential to assess disease progression and to evaluate the effectiveness of rehabilitation protocols and clinical treatments.
AIM
OBJECTIVE
The purpose of this study was to develop a touch-screen application, that we named 15-White Dots APP-Coo-Test (15-WDACT), able to carry out quantitative and objective measurements of the rapid and coordinated upper limb movements, typically impaired in patients with cerebellar ataxias (CA).
METHODS
METHODS
A total of 87 CA patients and 170 healthy subjects participated in this study. The subject was asked to touch with their index finger a white dot, appearing consecutively and randomly on the screen at different positions, for a total of 15 dots per session. The score is the execution time of a single session.
RESULTS
RESULTS
15-WDACT measurements have highly correlated with the scores obtained with the Scale for the Assessment and Rating of Ataxia (SARA), with the Composite Cerebellar Functional Severity (CCFS) and with the measurements obtained using two validated evaluating systems, i.e., the Nine Hole Pegboard test (9HPT) and the Click Test. We also observed high internal consistency and an excellent intra-rater and test-retest reliability. We found a small Standard Error of Measurement (SEM) and an excellent Minimal Detectable Change (MDC), indicating that even small variations in the 15-WDACT measurements are to be associated with real changes in performance.
CONCLUSIONS
CONCLUSIONS
We have concluded that 15-WDACT is an easy, fast and reliable tool to assess the severity of the upper limb ataxia in patients with CA.
Identifiants
pubmed: 30955123
doi: 10.1007/s00415-019-09299-9
pii: 10.1007/s00415-019-09299-9
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1611-1622Références
Mov Disord. 2002 Nov;17(6):1248-54
pubmed: 12465064
Am J Occup Ther. 2003 Sep-Oct;57(5):570-3
pubmed: 14527120
Lancet Neurol. 2004 May;3(5):291-304
pubmed: 15099544
Mov Disord. 2006 May;21(5):699-704
pubmed: 16450347
Phys Ther. 2006 May;86(5):735-43
pubmed: 16649896
Neurology. 2006 Jun 13;66(11):1717-20
pubmed: 16769946
Mov Disord. 2007 Aug 15;22(11):1633-7
pubmed: 17516493
J Hum Genet. 2007;52(10):848-55
pubmed: 17805477
J Neurol Sci. 2008 Mar 15;266(1-2):164-6
pubmed: 17950753
Brain. 2008 May;131(Pt 5):1352-61
pubmed: 18378516
Neurology. 2008 Aug 12;71(7):486-92
pubmed: 18695159
J Rehabil Med. 2009 Apr;41(5):343-6
pubmed: 19363567
Neurology. 2010 Feb 23;74(8):678-84
pubmed: 20177122
Cerebellum. 2012 Mar;11(1):194-211
pubmed: 21717229
Orphanet J Rare Dis. 2013 Jan 18;8:14
pubmed: 23331413
Cerebellum. 2016 Jun;15(3):369-91
pubmed: 26105056
Ann Clin Transl Neurol. 2016 Jul 25;3(9):684-94
pubmed: 27648458
Lancet Neurol. 2016 Dec;15(13):1346-1354
pubmed: 27839651
J Neurol Neurosurg Psychiatry. 2018 Jun;89(6):559-565
pubmed: 29279305
Lancet Neurol. 2018 Apr;17(4):327-334
pubmed: 29553382
Handb Clin Neurol. 2018;154:329-339
pubmed: 29903450
Mov Disord Clin Pract. 2016 Feb 11;3(3):230-240
pubmed: 30363623